Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01317043
Other study ID # RTOG 0622
Secondary ID
Status Recruiting
Phase Phase 2
First received March 11, 2011
Last updated March 16, 2011
Start date July 2007

Study information

Verified date March 2011
Source Sentara Norfolk General Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The pupose of this study is to assess the effectiveness of Samarium 153 administration, as determined by a 30% decline in the PSA within 12 weeks, as compared to baseline, in a population of men with high risk, clinically non-metastatic prostate cancer after a radical prostatectomy.


Description:

Patients with high-risk and clinically non-metastatic cancer who have a rising PSA level after a radical prostatectomy are elgible to enter this phase II trial. Initially, patients will receive Samarium 153 2.0 mCi/kg as an IV injection by the radiation oncologist one time. Twelve weeks later toxicity and PSA response will be evaluated. Next patients will receive 3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa. If there is no PSA response at 24 weeks, patients will begin hormonal therapy at the discretion of their physicians for a suggested 2 year period.


Recruitment information / eligibility

Status Recruiting
Enrollment 76
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria:

Pathologically (histologically) proven diagnosis of prostate cancer progressing after radical prostatectomy as indictated by one of the following:

- Postoperative PSA rising above 2.0ng/ml; or

- Postoperative PSA rising above 0.2 ng/ml with a surgical tumor Gleason score of 9 or 10; or

- Rapidly rising PSA profile with a doubling time less than 6 months.

- PSA Doubling Time (PSADT) should be calculated via the Calculation of PSA Doubling Time page on the RTOG web site http://www.rtog.org/psadt.html

- Pathologic stage T2 - T4 N0 - N1, including no distant metastases, based upon the following minimum diagnostic workup:

- History/physical examination within 8 weeks prior to registration

- Bone scan negative for bone metastases within 4 months prior to registration

- Abdominal imaging negative for metastases within 6 mothns prior to registration

- Zubrod Performance Status 0-1

- Age greater than or equal to 18 years.

- CBC/differential and PSA obtained within 4 weeks prior to registration, with adequate bone marrow function defined as follows:

- Absolute Neutrophil Count (ANC) greater than or equal to 1,800 cells/mm³

- Platelets greater than or equal to 100,000 cells/mm³

- Hemoglobin (Hgb) greater than or equal to 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb greater than or equal to 8.0 g/dl is permitted)

- Patients must be able to provide study specific informed consent prior to study entry.

Exclusion Criteria:

- Biopsy evidence of M1 disease

- Presence of neuroendocrine features in any prostate cancer specimen

- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years

- Prior systemic chemotherapy for the study cancer (Note: Prior chemotherapy for a different cancer is permitted.)

- Hormonal therapy initiated within the last 3 months

- Prior radiotherapy to the pelvic region that would result in overlap of radiation therapy fields

- Severe, active co-morbidity, defined as follows:

- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months

- Transmural myocardial infarction within the last 6 months

- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects (Note: Laboratory tests for liver function and coagulation parameters, however, are not required for entry into this protocol.)

- Renal failure (Note: Laboratory tests for renal function, however, are not required for entry into this protocol.)

- Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition (Note: HIV testing is not required). The need to exclude patients with AIDS is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Drug:
Samarium/IMRT
Initially, patients will receive Samarium 153 2.0 mCi/kg as an IV injection by the radiation oncologist one time. Twelve weeks later toxicity and PSA response will be evaluated. Next patients will receive 3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa. If there is no PSA response at 24 weeks, patients will begin hormonal therapy at the discretion of their physicians for a suggested 2 year period.
Samarium ethylenediaminetetramethylenephosphonate


Locations

Country Name City State
United States Sentara Norfolk General Hospital Norfolk Virginia

Sponsors (2)

Lead Sponsor Collaborator
Sentara Norfolk General Hospital Radiation Therapy Oncology Group

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT00673205 - (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer Phase 3
Completed NCT00672282 - Casodex vs Placebo in Non-Metastatic Early Prostate Cancer Phase 3
Recruiting NCT06202248 - A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer N/A
Completed NCT06204302 - An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
Completed NCT00239291 - Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer Phase 1/Phase 2
Recruiting NCT04049747 - Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer N/A
Active, not recruiting NCT05617885 - Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer Phase 1/Phase 2
Completed NCT00657904 - Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer Phase 3